Investigating a new immunotherapy for lung cancer using Interleukin 33
Study of Interleukin 33 as a new immunotherapy of lung cancer
This study is looking at how a special molecule called IL-33 can help boost the immune system's fight against lung cancer, with the hope that it could make current treatments like chemotherapy work better for patients.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Hackensack University Medical Center NIH-funded |
| Lab location | 1 site (Hackensack, United States) |
| Project ID | NIH-10654777 on NIH RePORTER |
What this research studies
This research focuses on enhancing the immune response against lung cancer by utilizing a molecule called Interleukin 33 (IL-33), which acts as a 'danger' signal to stimulate the immune system. The study aims to understand how IL-33 is down-regulated in lung cancer cells and how restoring its levels can improve the effectiveness of existing cancer treatments, such as chemotherapy and immune checkpoint blockade therapy. By using mouse models, researchers will explore the potential of IL-33 to reprogram the tumor microenvironment and boost the immune response against tumors. Patients may benefit from this innovative approach if it leads to more effective treatment options for lung cancer.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with lung cancer who may benefit from novel immunotherapy approaches.
Not a fit: Patients with lung cancer who have already exhausted all treatment options or those with non-malignant conditions may not receive benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a new immunotherapy option that enhances the effectiveness of current lung cancer treatments.
How similar studies have performed: Other research has shown promising results with similar immunotherapy approaches, indicating potential for success in this area.
Where this research is happening
Hackensack, United States
- Hackensack University Medical Center — Hackensack, United States (Active)
Researchers
- Principal investigator: Lu, Binfeng — Hackensack University Medical Center
- Study coordinator: Lu, Binfeng
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.